Provided is a method for preparing genetically-modified T cells expressing chimeric antigen receptor, comprising: (i) a step of preparing non-proliferative cells holding a viral peptide antigen, which are obtained by stimulating a group of cells comprising T cells using an anti-CD3 antibody and an anti-CD28 antibody followed by culturing in the presence of the viral peptide antigen and a treatment for causing the cells to lose their proliferation capability; (ii) a step of obtaining genetically-modified T cells into which a target antigen-specific chimeric antigen receptor gene has been introduced using a transposon method; (iii) a step of mixing the non-proliferative cells prepared by step (i) with the genetically-modified T cells obtained by step (ii), and co-culturing the mixed cells; and (iv) a step of collecting the cells after culture.

An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and/or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.

A Trichoderma reesei mutant strain has a function of a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 2 is reduced. A method of producing a protein includes a step of cultivating the Tricho-derma reesei mutant strain, and a method of producing a cellulase includes a step of cultivating the Trichoderma reesei mutant strain.

A Trichoderma reesei mutant strain has a function of a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 2 is reduced. A method of producing a protein includes a step of cultivating the Tricho-derma reesei mutant strain, and a method of producing a cellulase includes a step of cultivating the Trichoderma reesei mutant strain.

An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and/or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and/or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.

Provided is a method for predicting the onset of chorioamnionitis, which may predict the onset of chorioamnionitis with high sensitivity. The method including obtaining a base sequence data group of a 16S ribosomal RNA gene in a sample from the vagina of a subject; detecting the presence of a bacterium selected from a bacterial group represented by G1 below based on the data group obtained; and associating the sample with the likelihood of onset of chorioamnionitis based on the number of bacterial species detected. The bacterial group G1: Finegoldia magna; Streptococcus anginosus; Aerococcus christensenii; Lactobacillus jensenii; Ureaplasma parvum; Prevotella disiens; Lactobacillus vaginalis; Prevotella buccalis; Dialister micraerophilus; Atopobium vaginae; Prevotella bivia; Prevotella amnii; Anaerococcus lactolytcus; Streptococcus agalactiae; Anaerococcus tetradius; Bacteroides fragilis; Gardnerella vaginalis; Mycoplasma hominis; and Sneathia sanguinegens.

Serum albumin-free media comprising polyvinyl alcohol (PVA) and methods of culturing immune cells in such media are disclosed. The PVA is used as a replacement for fetal bovine serum, bovine serum albumin, and recombinant serum albumin in media. Advantages of using PVA include that it is a chemically-defined reagent that is available at high-purity with minimal batch-to-batch variability.

Serum albumin-free media comprising polyvinyl alcohol (PVA) and methods of culturing immune cells in such media are disclosed. The PVA is used as a replacement for fetal bovine serum, bovine serum albumin, and recombinant serum albumin in media. Advantages of using PVA include that it is a chemically-defined reagent that is available at high-purity with minimal batch-to-batch variability.

The present invention relates to a low-serum medium composition for culturing Vero cells, and a method for culturing Vero cells and a method for producing a virus, both using the same.

The present invention relates to a low-serum medium composition for culturing Vero cells, and a method for culturing Vero cells and a method for producing a virus, both using the same.